Abstract
Transient Receptor Potential Vanilloid 1 (TRPV1) is a Ca2+ permeant non-selective cation channel expressed in a subpopulation of primary afferent neurons. TRPV1 is activated by physical and chemical stimuli. It is critical for the detection of nociceptive and thermal inflammatory pain as revealed by the deletion of the TRPV1 gene. TRPV1 is distributed in the peripheral and central terminals of the sensory neurons and plays a role in initiating action potentials at the nerve terminals and modulating neurotransmitter release at the first sensory synapse, respectively. Distribution of TRPV1 in the nerve terminals innervating blood vessels and in parts of the CNS that are not subjected to temperature range that is required to activate TRPV1 suggests a role beyond a noxious thermal sensor. Presently, TRPV1 is being considered as a target for analgesics through evaluation of different antagonists. Here, we will discuss the distribution and the functions of TRPV1, potential use of its agonists and antagonists as analgesics and highlight the functions that are not related to nociceptive transmission that might lead to adverse effects.
Keywords: TRPV1, nociceptors, protein kinases, inflammatory mediators, pain, nociceptive ion channels
Current Neuropharmacology
Title: TRPV1: A Target for Next Generation Analgesics
Volume: 6 Issue: 2
Author(s): Louis S. Premkumar and Parul Sikand
Affiliation:
Keywords: TRPV1, nociceptors, protein kinases, inflammatory mediators, pain, nociceptive ion channels
Abstract: Transient Receptor Potential Vanilloid 1 (TRPV1) is a Ca2+ permeant non-selective cation channel expressed in a subpopulation of primary afferent neurons. TRPV1 is activated by physical and chemical stimuli. It is critical for the detection of nociceptive and thermal inflammatory pain as revealed by the deletion of the TRPV1 gene. TRPV1 is distributed in the peripheral and central terminals of the sensory neurons and plays a role in initiating action potentials at the nerve terminals and modulating neurotransmitter release at the first sensory synapse, respectively. Distribution of TRPV1 in the nerve terminals innervating blood vessels and in parts of the CNS that are not subjected to temperature range that is required to activate TRPV1 suggests a role beyond a noxious thermal sensor. Presently, TRPV1 is being considered as a target for analgesics through evaluation of different antagonists. Here, we will discuss the distribution and the functions of TRPV1, potential use of its agonists and antagonists as analgesics and highlight the functions that are not related to nociceptive transmission that might lead to adverse effects.
Export Options
About this article
Cite this article as:
Premkumar S. Louis and Sikand Parul, TRPV1: A Target for Next Generation Analgesics, Current Neuropharmacology 2008; 6 (2) . https://dx.doi.org/10.2174/157015908784533888
DOI https://dx.doi.org/10.2174/157015908784533888 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microdialysis Approach to Study Serotonin Outflow in Mice Following Selective Serotonin Reuptake Inhibitors and Substance P (Neurokinin 1) Receptor Antagonist Administration: A Review
Current Drug Targets Studies on the Pathophysiology and Genetic Basis of Migraine
Current Genomics Development of RET Kinase Inhibitors for Targeted Cancer Therapy
Current Medicinal Chemistry Accelerated Delimitation of the Infarct Zone by Capillary-Derived Nestin- Positive Cells in Aged Rats
Current Neurovascular Research PCSK9 Inhibitors for the Management of Dyslipidemia in People with Type 2 Diabetes: How Low is Too Low?
Current Pharmaceutical Design Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Association of <i>FOXP3</i> Polymorphisms with Susceptibility to Multiple Sclerosis: A Meta-Analysis on Genetic Association Studies
Current Pharmacogenomics and Personalized Medicine Stem Cell Niche in Tissue Homeostasis, Aging and Cancer
Current Medicinal Chemistry KCa3.1 Channels and Glioblastoma: In Vitro Studies
Current Neuropharmacology Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design Understanding and Improving Treatment Adherence in Patients with Psychotic Disorders: A Review and a Proposed Intervention
Current Psychiatry Reviews Prematurity and Morbidity: Could KMC Reverse the Process?
Current Women`s Health Reviews Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) New Approaches in the Management of Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Editorial (Thematic Issue: Introduction to 'Beneficial Effects of Psychedelics with a Special Focus on Addictions')
Current Drug Abuse Reviews QSAR Modeling of Histamine H3R Antagonists/inverse Agonists as Future Drugs for Neurodegenerative Diseases
Current Neuropharmacology Effects of α-Synuclein Overexpression in Transgenic Caenorhabditis elegans Strains
CNS & Neurological Disorders - Drug Targets Combination of Memantine and 6-Chlorotacrine as Novel Multi-Target Compound against Alzheimer’s Disease
Current Alzheimer Research Dermatologic Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Microbial Biofilms: Impact on the Pathogenesis of Periodontitis, Cystic Fibrosis, Chronic Wounds and Medical Device-Related Infections
Current Topics in Medicinal Chemistry